Skip to main content
Medexus Pharmaceuticals Inc. logo

Medexus Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · MDP ISIN · CA58410Q2036 LEI · 8945002TBEYY0HLH1M19 TSX Manufacturing
Open in API
Filings indexed 638 across all filing types
Latest filing 2024-09-16 Regulatory Filings
Country CA Canada
Listing TSX MDP

About Medexus Pharmaceuticals Inc.

https://www.medexus.com/en_US

Medexus Pharmaceuticals, Inc. is an innovative specialty pharmaceutical company engaged in the development and commercialization of treatment solutions. The company utilizes a highly scalable North American business model, leveraging a fully integrated infrastructure encompassing commercial operations, supply chain, regulatory affairs, and a dedicated salesforce. Medexus focuses on building a portfolio of specialty and rare disease products across key therapeutic areas, including hematology, hematology-oncology, allergy, dermatology, and rheumatology. Its mission is to deliver quality healthcare products to patients and healthcare professionals.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings
2024-09-16 English
Form of proxy - English.pdf
AGM Information Classification · 100% confidence The document is a Form of Proxy for the Annual Meeting of Medexus Pharmaceuticals Inc. scheduled for September 19, 2024. It includes instructions for appointing proxyholders, voting on election of directors, appointment of auditors, and other procedural details related to the Annual General Meeting (AGM). There is no financial data, management discussion, or detailed report content. The document is clearly related to the AGM and is a proxy solicitation form, which is part of AGM materials. Therefore, the document fits the category of AGM Information (AGM-R).
2024-08-16 English
Other.pdf
Report Publication Announcement Classification · 95% confidence The document is a short notice informing readers about the availability of a mandatory report related to the Supply Chains Act. It provides links to where the full report can be viewed or downloaded and instructions for obtaining paper copies. The document itself does not contain the report or substantive financial data but merely announces the report's availability. The length is only 1459 characters, which is quite short and consistent with an announcement rather than the report itself. Therefore, according to the 'Menu vs Meal' rule, this document should be classified as a Report Publication Announcement (RPA).
2024-08-16 English
Notice of meeting - English.pdf
AGM Information Classification · 100% confidence The document is a Notice of Annual Meeting of Shareholders for Medexus Pharmaceuticals Inc. It includes details about the meeting date, time, virtual attendance instructions, agenda items such as receiving audited financial statements, electing directors, appointing auditors, and proxy voting instructions. It explicitly states it is a notice for the annual meeting and includes a Management Information Circular attached. There is no actual financial data or report content included, only an announcement and instructions related to the AGM. The document length is about 5,157 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, this document is best classified as AGM Information (AGM-R).
2024-08-16 English
Management information circular - English.pdf
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Notice of Annual Meeting of Shareholders and a Management Information Circular for Medexus Pharmaceuticals Inc. It includes details about the annual meeting date, voting procedures, proxy solicitation, record date, and instructions for shareholders. It references the audited consolidated annual financial statements and the auditor's report to be received at the meeting but does not contain the financial statements themselves. The document is primarily intended to inform shareholders about the meeting and solicit proxies, which aligns with the definition of Proxy Solicitation & Information Statement (PSI). It is not the Annual Report (10-K) or the audited financial statements themselves, nor is it a voting results announcement or a regulatory filing. The length and content confirm it is a detailed proxy solicitation document with management information circular included.
2024-08-16 English
Other.pdf
Environmental & Social Information Classification · 95% confidence The document is titled 'Supply Chains Act Report' for the financial year ended March 31, 2024, prepared by Medexus Pharmaceuticals Inc. It details the company's policies, risk assessments, and compliance efforts related to forced labor and child labor in its supply chains, as required by Canada's Supply Chains Act. The content focuses on environmental, social, and governance (ESG) factors, specifically labor practices and human rights compliance. It is a standalone report addressing social responsibility and compliance with new legislation, not a financial report, earnings release, or management discussion. It does not announce voting results, capital changes, or legal proceedings. The document is comprehensive and substantive, not a brief announcement or certification. Therefore, the most appropriate classification is Environmental & Social Information (SR).
2024-08-16 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.